港股生物医药板块拉升，百济神州涨超6%

Core Viewpoint - The Hong Kong stock market's biopharmaceutical sector experienced a significant rally, with notable gains from companies such as BeiGene, which rose over 6%, along with other firms like Tigermed and CanSino Biologics also seeing increases [1] Group 1 - The biopharmaceutical sector in Hong Kong is showing positive momentum, indicating investor confidence and potential growth opportunities [1] - BeiGene's stock price increased by more than 6%, highlighting its strong market performance [1] - Other companies in the sector, including Tigermed and CanSino Biologics, also experienced upward movement, suggesting a broader trend within the industry [1]